# Gabriele Simonini

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/gabriele-simonini/

## Facts

| Field | Value |
| --- | --- |
| Citations | 7,240 |
| Field | Autoimmune and Inflammatory Disorders Research |
| h-index | 46 |
| i10-index | 160 |
| Last Known Institution | Meyer Children's Hospital |
| OpenAlex ID | https://openalex.org/A5014401271 |
| ORCID iD | 0000-0002-5919-4861 |
| Works | 411 |

## Researcher papers

- [Evidence of the transient nature of the Th17 phenotype of CD4+CD161+ T cells in the synovial fluid of patients with juvenile idiopathic arthritis](https://scholariq.org/papers/evidence-of-the-transient-nature-of-the-th17-phenotype-of-cd4-cd161-t-cells-in/)
- [Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative](https://scholariq.org/papers/consensus-based-recommendations-for-the-management-of-uveitis-associated-with/)
- [Prevention of flare recurrences in childhood‐refractory chronic uveitis: An open‐label comparative study of adalimumab versus infliximab](https://scholariq.org/papers/prevention-of-flare-recurrences-in-childhood-refractory-chronic-uveitis-an-open/)
- [Differentiating PFAPA Syndrome From Monogenic Periodic Fevers](https://scholariq.org/papers/differentiating-pfapa-syndrome-from-monogenic-periodic-fevers/)
- [Safety and Efficacy of Infliximab and Adalimumab for Refractory Uveitis in Juvenile Idiopathic Arthritis: 1-year Followup Data from the Italian Registry](https://scholariq.org/papers/safety-and-efficacy-of-infliximab-and-adalimumab-for-refractory-uveitis-in/)
- [Long-term efficacy and safety of infliximab plus methotrexate for the treatment of polyarticular-course juvenile rheumatoid arthritis: findings from an open-label treatment extension](https://scholariq.org/papers/long-term-efficacy-and-safety-of-infliximab-plus-methotrexate-for-the-treatment/)
- [Clinical and transcriptional response to the long‐acting interleukin‐1 blocker canakinumab in Blau syndrome–related uveitis](https://scholariq.org/papers/clinical-and-transcriptional-response-to-the-long-acting-interleukin-1-blocker/)
- [Current evidence of methotrexate efficacy in childhood chronic uveitis: a systematic review and meta-analysis approach](https://scholariq.org/papers/current-evidence-of-methotrexate-efficacy-in-childhood-chronic-uveitis-a/)
- [Anakinra treatment in drug-resistant Behcet’s disease: a case series](https://scholariq.org/papers/anakinra-treatment-in-drug-resistant-behcet-s-disease-a-case-series/)
- [Incidence of occult cancer in children presenting with musculoskeletal symptoms: A 10-year survey in a pediatric rheumatology unit](https://scholariq.org/papers/incidence-of-occult-cancer-in-children-presenting-with-musculoskeletal-symptoms/)
- [Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis](https://scholariq.org/papers/changing-evidence-over-time-updated-meta-analysis-regarding-anti-tnf-efficacy-in/)
- [To switch or to swap? Evidence from a meta-analysis for the best treatment approach in childhood chronic uveitis resistant to the I anti-TNF](https://scholariq.org/papers/to-switch-or-to-swap-evidence-from-a-meta-analysis-for-the-best-treatment/)

## Researcher topics

- [Autoimmune and Inflammatory Disorders Research](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders-research/)
- [Ocular Diseases and Behçet’s Syndrome](https://scholariq.org/topics/ocular-diseases-and-behcet-s-syndrome/)
- [Kawasaki Disease and Coronary Complications](https://scholariq.org/topics/kawasaki-disease-and-coronary-complications/)
- [Inflammasome and immune disorders](https://scholariq.org/topics/inflammasome-and-immune-disorders/)
- [Systemic Lupus Erythematosus Research](https://scholariq.org/topics/systemic-lupus-erythematosus-research/)

## Researcher university

- [Meyer Children's Hospital](https://scholariq.org/institutions/meyer-children-s-hospital-2/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.